Plain-English translation of NCT06925542 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called , which uses immune cells from healthy donors that have been genetically edited in the laboratory to fight autoimmune diseases. The cells are designed to target and reduce a specific type of immune cell (CD19) that is overactive in diseases like lupus, systemic sclerosis, and inflammatory myopathies. This is an early-stage study to see if the medication is safe and works in adults whose disease has not improved with standard treatments.
Current treatments don't work well enough for everyone with these severe autoimmune diseases, and some patients run out of options. Researchers are testing whether this new approach—using genetically modified immune cells—could offer hope to patients whose diseases have become resistant to standard medications.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would first receive chemotherapy to prepare your immune system, then receive the genetically modified cells through an intravenous infusion. You would then be closely monitored with regular clinic visits and blood tests to watch for side effects and to see whether the treatment is working. The study will follow you over time to understand both the safety and effectiveness of this new approach.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States